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Abstract 
Knowledge of the molecular mechanisms on malignant tumors is very critical for the development of new treatment 
strategies like molecularly targeted therapies. In last 5 years, many investigations suggest that stathmin is over-
expressed in a variety of human malignant tumors, and potentially promotes the occurrence and development of 
tumors. Rather, down-regulation of stathmin can reduce cell proliferation, motility and metastasis and induce apopto-
sis of malignant tumors. Thus, a stathmin antagonist, such as a specific inhibitor (antibody, small molecule compound, 
peptide, or siRNA), may be a novel strategy of molecular targeted therapy. This review summarizes the research 
progress of recent 5 years on the role of stathmin in tumorigenesis, the molecular mechanisms and development of 
anti-stathmin treatment, which suggest that continued investigations into the function of stathmin in the tumorigen-
esis could lead to more rationally designed therapeutics targeting stathmin for treating human malignant tumors.
Keywords: Cancer, Stathmin, Drug target, Anticancer therapy, Molecular targeted therapy
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
With the development of tumor molecular biology, pro-
gress of the detection and treatment of cancer has led to 
an impressive reduction in both mortality and morbidity. 
However, cancer still remains one of the most clinically 
challenging disease [1]. And the current first-line chem-
otherapy options, such as the combination of platinum-
based agents with paclitaxel, gemcitabine, vinorelbine, or 
docetaxel, seems to have reached a plateau of efficacy [2]. 
Especially, the resistance to traditional chemotherapeutic 
agents of tumors has become a very challenging problem. 
Therefore, more knowledge of the signal events of onco-
genesis is required for the development of new drugs [1].
Stathmin (also known as Op18, p18, p19, stathmin 1 or 
metablastin) has been found to be up-regulated in some 
cancers [3–6] and correlates with cell differentiation, pro-
liferation and migration, especially in solid tumor cells 
[7, 8]. Thus, stathmin may be an attractive target for drug 
design as targeting this molecule could simultaneously 
inhibit several aspects of tumor progression. Five years 
ago, Barbara Belletti [5] and Shushan Rana [6] made a 
summing up of relationship between stathmin and can-
cer. However, recent 5  years, many other studies refer-
ring the expression, mechanism and signal pathways of 
stathmin in tumors have been continuously reported, and 
some of them are very marked and impressive. It seems 
that this is an urgent request for cardinal significance that 
reviews the latest 5 years reports on new progress of this 
field. Here, we recapitulate the multiple roles of stathmin 
in cancer progression, the mechanisms and signal path-
ways of regulating the proliferation, apoptosis, migration 
of tumor cells, the pre-clinical results of stathmin inhi-
bition in various cancer models, and available data as 
rationale for the therapeutic manipulation of stathmin in 
cancer patients.
Stathmin: molecular structure and function domain
In spite of many years of research, knowledge of this mol-
ecule is still so obscure that some investigators even did 
not define its name certainly, which dues to the fact that 
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institutes. So, it is called by different names (e.g., p17, 
p18, p19, 19 K, metablastin, oncoprotein 18, LAP18, and 
stathmin 1, Op18/stathmin). Stathmin is composed of 
149 amino acids, which are organized into four domains 
(I–IV), and the core region (amino acids 42–126) is site 
for tubulin interaction with the additional requirement 
of either an N- or C-terminal extension [9]. The mem-
bers of stathmin family belong to microtubule-regulating 
proteins, which include stathmin (stathmin 1), SCG10, 
SCLIP, and RB3/RB3′/RB3′’coded by four different genes 
[9]. And, all stathmin family members have a highly con-
served stathmin-like domain. The stathmin-like domains 
of these proteins also possess a tubulin binding activity 
(Fig. 1).
The N-terminal and C-terminal of stathmin exert dif-
ferent functions when stathmin participate the molecu-
lar actions. The N-terminal of stathmin is the regulatory 
domain of stathmin. There are four phosphorylation 
domains on this region, designated as Ser 16, 25, 38 and 
63 [5], which intimately correlate with the functions of 
stathmin by kinases involved in major intracellular regu-
latory cascades. The C-terminal is interaction domain of 
stathmin, which includes a coiled-coil forming a-helical 
structure, potentially interacting with other different sig-
nal proteins to exert biological actions [10]. Stathmin is 
an ubiquitous cytosolic phosphoprotein, proposes to be 
a small regulatory protein and a relay integrating diverse 
intracellular signaling pathways involved in the control of 
cell proliferation, differentiation and activities [5]. Some 
downstream target and/or partner proteins participate 
the modulation process of stathmin and interact each 
other to exert biological actions through phosphorylation 
of stathmin (Fig. 1b).
Expression of stathmin in human malignant tumor
Stathmin expression has been examined in several 
types of cancer. We emphatically harvested the lasted 
5  year studies on this field. As shown in Table  1, stath-
min is highly expressed in a variety of assessed human 
malignancies including lung cancer [3, 11], esophageal 
Fig. 1 Structure diagram of stathmin and related signal patterns. Stathmin has a highly conserved stathmin-like domain (α-helical structure) and 
has four positions of serine phosphorylation sites (S16, S25, S38 and S63). The N- and C-terminal of stathmin exert different functions when 
stathmin participate the molecular actions. Some downstream target and/or partner proteins participate the modulation process of stathmin and 
interact each other to exert biological actions through phosphorylation of stathmin
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Table 1 Summary of stathmin expression in human tumors and correlation with clinical outcome
Publications Cancer type Cell lines Tissue Techniques Notes
Nie [3] Lung cancer Yes Yes qRT-PCR, IHC Overexpression of stathmin is a poor 
prognostic biomarker for non-small 
cell lung cancer
Sun [11] No Yes IHC, WB, qRT-PCR Overexpression of stathmin correlates 
with shorter overall survival and 
progression-free survival in non-small 
cell lung cancer
Wang [15] Esophageal carcinoma No Yes IHC, ISH Stathmin is associated with esophageal 
carcinoma (EC) development and 
progression and may be a good prog-
nostic marker for patients with EC
Wang [16] Yes Yes IHC, WB Stathmin is highly expressed in esopha-
geal squamous cell carcinoma Eca109 
and TE-1 cells
Liu [13] Yes Yes 2-DE and IHC Stathmin is overexpressed in esopha-
geal squamous cell carcinoma (ESCC) 
tissues
Akhtar [12] No Yes IHC, WB Stathmin overexpression predicts a high 
risk for lymphatic metastatic recur-
rence in pN0 esophageal squamous 
cell carcinoma patients
Baquero [17] Breast cancer No Yes IHC High stathmin expression predicts 
worse overall survival of breast cancer
Watanabe [18] Cholangiocarcinoma Yes Yes IHC, WB Stathmin correlates with shorter recur-
rence-free survival and overall survival 
in cholangiocarcinoma patients
Hsieh [4] Hepatocellular carcinoma Yes Yes IHC, WB Stathmin overexpression in hepatoma 
is associated with local invasion, early 
recurrence, and poor prognosis, and 
is an independent indicator for tumor 
recurrence
Ahn [19] Yes Yes IHC, WB Stathmin and EF1α increase as 
multistep hepatocarcinogenesis pro-
gressed, showing the highest levels in 
hepatocellular carcinomas
Chen [20] Yes Yes IHC, WB Upregulation of E2F1 and stathmin 
are associated with worse outcomes 
in patients with hepatocellular 
carcinoma
Li [24] Gastric cancer Yes Yes IHC, WB Stathmin is overexpressed in 103 post-
operational gastric cancer specimens
Liu [25] Yes Yes IHC, WB Stathmin is elevated in gastric cancer 
tissues, indicating a possible associa-
tion between the stathmin and the 
disease occurrence
Batsaikhan [21] No Yes IHC, ISH Higher stathmin is significantly associ-
ated with gender-and poorly differen-
tiated gastric adenocarcinoma
Kang [22] Yes Yes IHC,WB, qRT-PCR Stathmin is upregulated in gastric 
cancer cell lines and primary gastric 
adenocarcinomas, which is correlated 
with age, T stage and lymph node 
metastasis
Ke [23] No Yes IHC, WB, qRT-PCR Stathmin mRNA and protein in gastric 
cancer tissues are overexpressed, 
which correlates with Lauren’s clas-
sification, depth of invasion, lymph 
node metastases, and tumor node 
metastasis (TNM) stage
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Table 1 continued
Publications Cancer type Cell lines Tissue Techniques Notes
Lu [27] Pancreatic cancer Yes Yes IHC, WB Stathmin is over-expressed in pancre-
atic cancer tissues and correlates 
with vascular emboli, tumor size, and 
overall survival
Schimmack [28] Pancreatic neuroendocrine 
neoplasm
Yes Yes IHC,WB, qRT-PCR Stathmin mRNA and protein are overex-
pressed in pancreatic neuroendocrine 
neoplasm (pNENs) and correlate with 
pNEN tumor extension, size, and Ki67 
expression
Li [59] Yes Yes IHC, WB Stathmin is overexpressed to a large 
extent in pancreatic cancer tissues 
and cell lines
Machado-Neto [29] Myelodysplastic syndromes Yes Yes IHC, WB Higher stathmin level is observed in 
proliferating hematopoietic cells, 
high-risk myelodysplastic syndromes 
(MDS) and acute leukemia cells
Hsu [30] Nasopharyngeal carcinoma Yes Yes IHC, WB Higher stathmin expression is cor-
related with advanced age higher T 
stage and overall clinical stage
Birnie [31] Malignant pleural mesothelioma Yes No IHC, WB Stathmin expression is higher in 
malignant pleural mesothelioma cell 
lines when compared with primary 
mesothelial cell controls
Howitt [32] Cervical carcinomas No Yes IHC Stathmin is overexpressed in virtually 
all cervical carcinomas and cervical 
intraepithelial neoplasias 3 (CIN3) 
lesions
He [33] Endometrial carcinoma Yes Yes IHC Stathmin is up-regulated in endome-
trial carcinoma (EC), and elevated 
stathmin is correlated positively 
with tumor stage and lymph node 
metastasis
Wik [34] Yes Yes IHC, FISH, FCM, SNP High p-stathmin(S38) level is associated 
with poor prognosis, independent of 
other features.
Bhagirath [37] Bladder urothelial carcinoma No No ELISA, qRT-PCR The urinary level of serum stathmin 
concentration shows a specific 
increase in patients with urothelial 
carcinoma of the bladder as com-
pared to the controls
Wosnitzer [35] No Yes Immunophenotype 
analysis
Increased total tau (cytoplasmic and 
nuclear) and stathmin before intra-
vesical taxane therapy is significantly 
associated with decreased recur-
rence-free survival
Hemdan [36] No Yes IHC,WB High stathmin expression correlates 
to shorter disease-specific survival 
hazard ratio, elevated p53 and Ki67-
protein levels
Tan [38] Colorectal cancer Yes Yes 2-D DIGE Stathmin is found to be highly up-
regulated in colorectal cancer E1 cells 
as compared to HCT-116 cells
Marie [39] Glioblastoma Yes Yes qRT-PCR Stathmin expression is significantly 
increased in malignant diffusely infil-
trative astrocytomas compared with 
pilocytic astrocytoma
qRT-PCR real-time quantitative reverse transcription polymerase chain reaction, IHC immunohistochemistry, WB west blotting, ISH in situ hybridization, 2-DE 
two-dimensional gel electrophoresis, FISH fluorescence in situ hybridization, FCM flow cytometry, SNP single nucleotide polymorphism, ELISA enzyme-linked 
immunosorbent assay, 2-D DIGE two dimension difference gel electrophoresis, EC esophageal carcinoma, ESCC esophageal squamous cell carcinoma, EF1α EF1α 
promoter, E2F1 E2F transcription factor 1, mRNA messenger RNA, TNM tumor node metastasis classification of malignant tumours, pNENs pancreatic neuroendocrine 
neoplasm, Ki67 Ki67 gene, MDS myelodysplastic syndromes, CIN3 cervical intraepithelial neoplasias 3 grades, EC endometrial carcinoma, E1 and HCT-116 colorectal 
cancer cell lines
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carcinoma [12–16], breast cancer [17], cholangiocarci-
noma [18], hepatocellular carcinoma [4, 19, 20], gastric 
cancer [21–25], pancreatic cancer [26–28], myelodys-
plastic syndromes [29], nasopharyngeal carcinoma [30], 
malignant pleural mesothelioma [31], cervical carcino-
mas [32], endometrial carcinoma [33, 34], urothelial car-
cinoma of the bladder [35–37], colorectal cancer [38] and 
glioblastoma [39]. And, high expression of stathmin inti-
mately correlates with the malignant behavior and clini-
cal features of tumor.
With regard to detection of stathmin, most of the stud-
ies adopted two levels of cell and tissues. immunohisto-
chemistry (IHC) analysis for stathmin was adopted by 
almost every study and some even include west blotting. 
However, most if not all of the studies are concordant 
with the notion that stathmin expression and/or activ-
ity are up-regulated in human cancer. Specifically, seven 
studies adopted extra detection of qRT-PCR [3, 11, 22, 
23, 28, 37, 39] and two adopted the methods of 2-DE [13, 
38], which are all belonged to available methods. Impres-
sively, stathmin overexpression is associated with poor 
survival and local or distant metastasis formation in sev-
eral types of human cancer including lung cancer [11], 
esophageal carcinoma [12], breast cancer [17], cholangio-
carcinoma [18], hepatocellular carcinoma [4, 20], gastric 
cancer [22, 23, 25], pancreatic cancer [27] and endome-
trial carcinoma [33–35, 37]. These data strongly indicate 
that stathmin has a potential to become a prognostic 
index and tumor marker for malignant cancers.
However, there are some limitations on these studies. 
First, only surgical specimens were used in some studies, 
which results in a major patient selection bias. Second, 
the number of samples of some studies is relatively small. 
Thus, further investigations into different cancers exten-
sively involving a larger number of samples of patients is 
required to reach a more definitive conclusion. Despite 
all this, these studies elucidate that stathmin potentially 
contributes to tumor development and progression, sug-
gesting that its high expression is not only required, but 
also detrimental during stages of cancer onset [40].
New progress regarding to biological function of stathmin 
on malignant tumor
Stathmin interferes with microtubule dynamics on cancer 
cells
This part mainly describes the relationship between reg-
ulation of microtubule dynamics and role of stathmin 
in malignant tumors, as well as prospects or proposals 
of research. Microtubules are essential for the structure 
and function of the cell that relate to intracellular trans-
port, cell motility and polarity [6]. When cell turns into 
mitosis, microtubules become the major component 
of mitotic spindle which enables correct chromosome 
segregation [10]. As shown in Fig.  2a, the alteration of 
microtubules is tided up with many crucial processes 
such as cell proliferation, mitosis and motility, which is 
controlled by the phosphorylation of stathmin by two 
phases causing biphasic shifts in microtubules stabil-
ity/instability [41]. Epithelial-mesenchymal transition 
(EMT) plays a positive role in growth and migration of 
tumor cells. As a microtubule-destabilizing protein, 
stathmin can promote malignant potential for cancer 
cells by initiating EMT [10]. Research shows the micro-
tubule-destabilizing activity of stathmin contributes to 
EMT via stathmin-microtubule-EMT (S-M-E) axis dur-
ing cancer development [10]. Phosphoinositide 3-kinase 
PI3  K/mTOR/HSP90 is shown as a possible signal tar-
get for p-stathmin S38- high-endometrial cancer cases. 
High p-stathmin (S38) correlates with PI3 K pathway and 
increase PIK3CA copy number (FISH) and a PI3 K acti-
vation score [34].
Siva1, an apoptosis-inducing factor, inhibits stathmin’s 
activity directly as well as indirectly through Ca(2+)/
calmodulin-dependent protein kinase II-mediated phos-
phorylation of stathmin at Ser16, which enhances the 
formation of microtubules and impedes focal adhesion 
assembly and EMT. And low levels of Siva1 and Ser16-
phosphorylated stathmin correlate with high metastatic 
states of human breast cancer cells [42]. The p90 riboso-
mal S6 kinase 2 (RSK2) has been identified to promote 
tumor metastasis; latest one study demonstrates that 
RSK2 directly phosphorylates stathmin and regulates 
microtubule polymerization to provide a pro-invasive 
and pro-metastatic advantage to cancer cells [43].
One potential target of the MAPKs is stathmin and the 
activity of MAPK is induced by the Epstein-Barr virus-
encoded latent membrane protein 1 (LMP1). Research 
shows LMP1 regulates stathmin signaling, which is 
mainly mediated by ERK. The inhibition of LMP1 expres-
sion attenuates the interaction of ERK with stathmin and 
promotes microtubule depolymerization [44]. Stathmin 
depletion causes significant inhibition of HGF-induced 
WAVE2 transport and lamellipodia formation. Pak1 
plays a critical role in this effect on phosphorylation and 
recruitment of tubulin-bound stathmin/Op18 to the 
complex [45]. Stathmin silencing also reduces the activity 
of CDC25, Aurora A and Plk1. Research shows MTs con-
tribute to Plk1 activation, and stathmin regulates mitotic 
entry via MTs to control localization and activation of 
both Aurora A and Plk1 [46] (Fig. 2b).
In the interphase of cell cycle, increased stathmin 
damages nucleation from centrosome. Homo sapiens 
leucine rich repeat containing 4 (LRRC4) is epigeneti-
cally inactivated commonly in glioma. Knockdown of 
stathmin induces cell cycle arrest of glioma U251 cells 
and increases the microtubulin polymerization of U251 
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cells. And down-regulation of stathmin inhibits CDK5 
and cdc2 kinase, which correlates with the modulation of 
the p21, cyclin D1, and cyclin B expression, and the situ-
ation of ERK phosphorylation [47] (Fig. 2c). Overall, the 
microtubule-destabilizing protein stathmin is involved in 
cancer development. Most interestingly, stathmin and its 
microtubule-depolymerizing activity intimately correlate 
with EMT progress, which is involved in tumor malig-
nant progression and recurrence, even in resistance of 
chemotherapy. Thus, further investigations into this pro-
cess of stathmin-microtubule dynamics should be done.
Stathmin correlates with proliferation of cancer cells
Stathmin is an important member of a family of micro-
tubule-destabilizing proteins [48], which has been proved 
to exert critical actions in control of cell proliferation 
[5]. Several observations suggest that there is a close 
link between stathmin expression and/or phosphoryla-
tion and regulation of cellular proliferation in cancers. 
Knockdown of stathmin leads to cell cycle arrest in G2/M 
phase in esophageal carcinoma cells [16] and pancre-
atic cancer cells and clonogenicity of Namalwa leukemia 
cells [29], and reduces the viability and colony forma-
tion. Adenovirus-mediated gene transfer of anti-stathmin 
ribozyme results in a dose-dependent inhibition of prolif-
eration and clonogenicity associated with a G2/M arrest 
and increases the apoptosis rate of both ER-positive and 
ER-negative breast cancer cells [48]. The CDK inhibitor 
p27(kip1) and p21(Cip1/Waf1) are critical regulators of 
cell cycle progression, which bind to stathmin as partners 
to control the early phase of G1 to S phase transition to 
the context of tumor progression [49]. Knockdown of 
stathmin results in a decrease in cellular proliferation and 
invasion in lung cancer cells [3] and in pancreatic neu-
roendocrine neoplasm cells, and PI3 K inhibitors directly 
inhibits proliferation via stathmin inactivation [28]. Fur-
thermore, silence of stathmin down-regulates the expres-
sion of Nf-κB (p65), which indicates that stathmin might 
play its oncogenic role by an interaction with Nf-κB path-
way [27] (Fig. 3a).
Stathmin depletion suppresses the expression of 
hypoxia-induced factor-1α (HIF-1α) and VEGF, and 
impedes the phosphorylation of ribosomal protein S6 
kinase 1 (S6  K) and Akt, which means stathmin play a 
critical role in the mTOR/HIF-1α/VEGF signally pathway 
[50]. At molecular level, stathmin favours the binding and 
the phosphorylation of p53(MUT) by catalytic subunit of 
the DNA-dependent protein kinase (DNA-PKCS), modu-
lating p53(MUT) stability and transcriptional activity. 
Inhibition of stathmin or impediment of DNA-PKCS 
damage the p53(MUT)-dependent transcription lead to 
the failure of M phase and the death of epithelial ovar-
ian carcinomas (EOC) cells [8] (Fig. 3b). The down-regu-
lation of leucine zipper transcription factor (CREB1) and 
helix-loop-helix transcription factor (LYL1) reduce the 
expression of stathmin, which lead to inhibition of cell 
proliferation [51]. Knockdown of stathmin promotes the 
effects of indoly-chalcones CITs (CIT-026, CIT-214, CIT-
223) to bring down microtubule destabilization, result in 
cell death and decelerate cell proliferation [52]. In addi-
tion, stathmin enhances the growth and invasion of endo-
metrial carcinoma cells by regulating the secretion and 
activation of MMP2 and MMP9 [33]. And inhibition of 
Rlim (a Ring H2 zinc finger protein) increases the expres-
sion of stathmin, and leads to cell proliferation of human 
osteosarcoma cell lines [53]. Monoclonal antibodies 
Fig. 2 Stathmin interferes with microtubule dynamics. aThere is a stathmin-microtubule-EMT (S-M-E) axis during cancer development; stathmin 
promotes malignant potential in cancer cells by initiating EMT; phosphoinositide 3-kinase (PI3 K)/mTOR/HSP90 are suggested as possible targets 
in p-stathmin(S38)-high cases; b siva1 enhances the formation of microtubules and impedes adhesion, cell migration, and EMT by inhibiting 
stathmin’s activity; inhibition of LMP1 expression attenuates the interaction of ERK with stathmin and promotes microtubule depolymerization; 
c induction of LRRC4 or knockdown of stathmin induces cell cycle arrest by modulating the p21, cyclin D1, and cyclin B expression, and the ERK 
phosphorylation. PI3 K phosphoinositide 3-kinase, mTOR mammalian target of rapamycin, HSP90, heat shock protein 90, EMT epithelial-mesenchy-
mal transition, Siva proapoptotic protein, LMP1 latent membrane protein 1, ERK extracellular regulated protein kinases, RSK2 p90 ribosomal S6 kinase 
2, LRRC4 leucine rich repeat containing 4, CDK5 cyclin-dependent kinase-5, CDC2 cyclin-dependent kinase 1, p21 cyclin-dependent kinases
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against stathmin and paclitaxel have bee used alone or 
incombination to inhibit the proliferation of human lung 
carcinoma QG-56 cells, especially result in a significant 
apoptosis [54]. A novel tumor-specific RNA interference 
adenovirus system targeting Aurora A by using stathmin 
promoter not only inhibits the cells proliferation, but 
also enhance the chemosensitivity to paclitaxel in human 
breast carcinoma SK-BR-3 and MDA-MB-231 cells, and 
further decreases the phosphatidylinositol 3 kinase/Akt 
and p-BRCA1 protein expression [55]. Stathmin also 
plays a role in the development of fallopian tube epithe-
lium (FTE) tumor, which potentiate aberrant cell prolif-
eration, migration, and/or loss of polarity during early 
tumorigenesis, resulting from loss of p27-mediated regu-
lation [56] (Fig. 3c).
Stathmin correlates with apoptosis of cancer cells
Apoptosis, an orchestrated event in which cells are pro-
grammed to die after receiving specific stimuli, is an 
important component of cell growth control [57]. So 
far, many studies demonstrate that stathmin present an 
anti-apoptotic activity to prompt the progress of tumor 
cells and play an important role in control of cell cycles, 
which are involved in many signal molecules. Oxidative 
stress from menadione-generated superoxide induces 
JNK-dependent stathmin phosphorylation at Ser-16, Ser-
25 and Ser-38 in hepatocytes. Down-regulation of stath-
min promotes the sensitivity of apoptotic and necrotic 
cell death from menadione in hepatocytes [58]. Sup-
pression of stathmin not only inhibits the proliferation, 
migration and invasion of pancreatic cancer and naso-
pharyngeal carcinoma cells, but also enhances the apop-
tosis of cancer cells [59, 60]. And, stathmin knockdown 
improves the chemosensitivity of gastric cancer cells 
to docetaxel, making the percentage of cells at the sub-
G1 stage increase and promote apoptosis [61]. Research 
shows paclitaxel reduces the expression of stathmin, and 
combination of stathmin silencing with paclitaxel treat-
ment enhances microtubules polymerization and tumor 
cell apoptosis [60]. A selective JAK1/2 inhibitor, ruxoli-
tinib, has been reported to inhibit the JAK/STAT path-
way in myeloproliferative neoplasms. The JAK2(V617F) 
mutation potentially leads to inhibition of stathmin activ-
ity via constitutive STAT3 phosphorylation. Therefore, 
combination of stathmin silencing and ruxolitinib treat-
ment can reduce cell proliferation and clonal growth, and 
increase apoptosis induced by ruxolitinib [62] (Fig. 4a).
Glioma is common angiogenic tumor, which is always 
resistant to chemotherapy and radiotherapy. Research 
shows knockdown of stathmin inhibits the proliferation 
of glioma cells, induces apoptosis, arrests the cell cycle at 
G2/M phase in glioma stem cells (GSCs), and also sup-
presses the migration/invasion [63]. Down-regulation of 
stathmin transfected with stathmin shRNA significantly 
inhibits cell proliferation and tumorigenicity, arrests 
cell cycle in the G2/M phase and induces cell apoptosis. 
Fig. 3 Stathmin affects the proliferation of cancer cells. a Stathmin cooperates with p21(Cip1/Waf1) and p27(Kip) to control the early phase of G1 
to S phase and reduces tumor growth by down-regulation of Nf-κB; b stathmin knockdown inhibits the expression of HIF-1α and VEGF and phos-
phorylation of S6 K and Akt; stathmin binds phosphorylation of p53(MUT) by DNA-PKCS, but inhibition of stathmin or DNA-PKCS results in M phase 
failure by impairing p53(MUT)-dependent transcription; c down-regulation of CREB1 and LYL1 reduces cell proliferation by the down-regulating 
stathmin; knockdown of stathmin promotes the effects of indoly-chalcones CITs; stathmin enhances growth and invasion of EC by activating MMP2 
and MMP9; inhibition of Rlim increases expression of stathmin and leads to cell proliferation; inhibition of Aurora A by stathmin promoter inhibits 
cells proliferation by reducing expressions of phosphatidylinositol 3 kinase/Akt and p-BRCA1; stathmin potentiates cell proliferation by regulating 
function of p27. p21 cyclin-dependent kinases, p27 cell cycle checkpoints regulator protein, PI3 K phosphoinositide 3-kinase, Nf-κB nuclear factor 
‘kappa-light-chain-enhancer’ of activated B-cells, Akt v-akt murine thymoma viral oncogene, S6 K ribosomal protein S6 kinase 1, HIF-1α hypoxia-
inducible factor-1, VEGF vascular endothelial growth factor, p53 tumor suppressor p53, DNA-PKCS catalytic subunit of the DNA-dependent protein 
kinase, CREB1 leucine zipper transcription factor, LYL1 basic helix-loop-helix transcription factor, Rlim a Ring H2 zinc finger protein, MMP matrix 
metalloproteinases, p-BRCA1 phosphorylated phosphorylated breast cancer gene 1, CITs, indoly-chalcones
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Furthermore, down-regulation of stathmin result in 
downregulation of Bcl-2 and survivin proteins, activa-
tion of Caspase-3, which all are intimately related to the 
development and progress of tumors [14] (Fig. 4b).
Stathmin expression correlates with motility of cancer cells
The mobility and migration is very critical biological 
event in progress and proliferation of malignant tumors. 
If the tumor cells become migratory, this will possibly 
lead to the local and remote metastasis of malignant cells, 
which eventually speed up the disease progress. Stathmin 
is important member of microtubule-regulating proteins, 
cell migration is intimately associated with stathmin 
that interfere with microtubule dynamics by elevating 
depolymerization of microtubules. Overexpression of 
stathmin is strongly related to tumor aggressiveness of 
Fig. 4 Stathmin correlates with apoptosis and mobility of cancer cells. a Oxidative stress induces JNK-dependent stathmin phosphorylation, but 
down-regulation of stathmin promotes apoptosis of cells and inhibits proliferation and migration; stathmin silencing with paclitaxel enhances 
tumor cell apoptosis; JAK2(V617F) mutation potentially leads to inhibition of stathmin activity via STAT3 phosphorylation; b silencing of stathmin 
increases apoptosis of cells by down-regulating Bcl-2 and survivin and activating Caspase-3, and significantly arrests the cell cycle at G2/M phase; 
c stathmin attributes to E2F1 and/or Dp-1 (TFDP1) transactivation, knockdown of the E2F1 suppresses cancer cell migration; stathmin counteracts 
PDEF’s effects against cell migration; d SIVA silencing increases cell migration by promoting stathmin activity, but ANKHD1 silencing leads to stath-
min inactivation likely through inhibition of SIVA/stathmin association; MCPyV tumor antigen promotes the destabilization of the host cell micro-
tubule network by regulating phosphorylation of stathmin, which leads to migratory cell phenotype. JNK c-JunN-terminalkinase, JAK janus kinase, 
JAK janus kinase, STAT signal transducers and activators of transcription, Bcl-2 B cell lymphoma-2, E2F1 E2F transcription factor 1, TFDP1 transcription 
factor Dp-1, PDEF prostate-derived Ets transcription factor, SIVA proapoptotic protein, ANKHD1 ankyrin repeat and KH domain containing 1 protein, 
MCPyV Merkel cell polyomavirus
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nasopharyngeal carcinoma patients, which attributes to 
the transactivation of transcription factor 1 (E2F1) and/
or transcription factor Dp-1 (TFDP1) [30]. Down-regu-
lation of E2F1 results in reduction of stathmin in HCC 
lesions, suggesting that stathmin gene is transactivated 
by the E2F1 protein [20]. In addition, stathmin silenc-
ing significantly impedes cell proliferation and mobil-
ity of neuroblastoma cells, polyploidy of hepatoma cells 
[4] and esophageal squamous cell carcinoma cells [13], 
and remarkably retards cell migration and invasion [64]. 
Inversely, over-expression of stathmin enhances cell inva-
sion and causes polyploidy of hepatoma cells [4]. When 
the expression of stathmin is down-regulated in gastric 
adenocarcinoma cells, this significantly reduces cell pro-
liferation, colony formation and cell invasion and migra-
tion ability, and arrest cells in G1 phase [22]. It is reported 
that prostate-derived Ets transcription factor (PDEF) is 
present in breast and prostate cells and tissues. It seems 
that high expression of stathmin brings down the effects 
that PDEF inhibit cell proliferation, colony formation and 
tumor migration, and discloses that PDEF exert an anti-
tumor effects through down-regulating the expression of 
oncogenic stathmin [65] (Fig. 4c).
It is reported that the knockdown of proapoptotic 
protein SIVA activates the expression of stathmin, 
which promotes cell mobility and migration and the 
growth of xenotransplanted tumors, but silencing of 
ankyrin repeat and KH domain containing 1 protein 
(ANKHD1) plays an inverse function that leads to stath-
min inactivation, inhibits cell migration and the growth 
of xenotransplanted, which possibly depends on the 
inhibition mechanism of SIVA/stathmin pathway [66]. 
Merkel cell carcinoma (MCC) can be caused by Mer-
kel cell polyomavirus (MCPyV), which is an aggressive 
skin malignant tumor, and the migratory mechanism of 
MCC is more likely related to the function of stathmin. 
It is shown that MCPyV small tumor antigen enhances 
microtubule destabilization of the MCC cells by modu-
lating the phosphorylation status of stathmin, which 
results in the motility, migration and metastasis of Mer-
kel cell carcinoma [67] (Fig. 4d). Although many studies 
have identified that there is a strong relationship between 
overexpression of stathmin and increased migration and/
or metastatic trend of malignant tumors; much still has 
not been disclosed about the molecular signally pathways 
how stathmin performs the role on migration and metas-
tasis in cancer cells and how stathmin interactions with 
those special genes and proteins.
Stathmin and small non‑coding RNAs
Recent studies have revealed that small non-protein-cod-
ing regulatory RNAs (miRNAs, MicroRNAs) may regu-
late complex biological processes of malignant tumors 
including cell proliferation, differentiation and apoptosis. 
So far, over 2588 miRNAs have been identified in humans 
and the number of investigations is growing. Evidence on 
the relation between MicroRNAs and malignant tumor 
has been suggested that some aberrant miRNA expres-
sions promote the development of cancers, but the others 
play a negative function in tumorigenesis [68].
The chemoresistant ovarian cancer KF-TX cells present 
overexpression of stathmin, which is being considered to 
correlate with drug resistance. Down-regulation of stath-
min can partly renew taxane-sensitivity of KF-TX cells, 
and up-regulation of miR-31 can significantly recover 
chemo-sensitivity of KF-TX cells (KF-TX-miR-31) by 
reducing stathmin expression as well [69]. Stathmin is 
identified as an effective functional target of miR-101, 
which is related to cell proliferation, radioresistance of 
nasopharyngeal carcinoma (NPC) cells. The miR-101 
exert a critical action in radioresistance by modulating 
the expression of stathmin via miR-101/stathmin path-
way [70]. Down-regulation of miR-193b is closely asso-
ciated with overexpression of stathmin in melanoma, 
which is identified to be conducive to promote the migra-
tion and proliferation of tumor cells [71]. And study 
reveals that aberrant miR-223 contributes to aggressive-
ness of malignant pleural mesothelioma (MPM) by regu-
lating stathmin and both are also in turn regulated by the 
JNK signally pathway [31] (Fig. 5a).
Elevation of miR-193b impedes the ability of esopha-
geal cancer cells to recover following 5-fluorouracil 
(5-FU) treatment through the regulation of autophagy, 
which suggests that it may mediate some of its effects 
through stathmin regulation (potential autophagy regu-
lator) [72]. Interestingly, overexpression of miR-193b 
suppresses the proliferation, migration and invasion of 
pancreatic cancer Panc-1 cells by inhibiting the expres-
sion of stathmin and urokinase-type plasminogen activa-
tor (uPA) [26]. It is suggested that long term colonization 
of Helicobacter pylori in gastric mucosa increases the risk 
of gastric cancer. Stathmin is considered as a target of 
miR-210 and down-regulation of miR-210 increases the 
proliferation of gastric epithelial cells by activating stath-
min [73]. Specific transfection of miR-142 and miR-223 
influences post-transcriptional regulation of proteins in 
hepatocellular carcinoma (HCCs), which has a suppres-
sive effects on proliferation of hepatocellular carcinoma 
cells by regulating expressions of stathmin and insulin-
like growth factor-1 receptor (IGF-1R) [74] (Fig. 5b).
Stathmin has been identified as a functional target of 
microRNA-9. Up-regulation of microRNA-9 reduces gli-
oma cell proliferation, migration and vasculogenic mim-
icry by up-regulating the expression of stathmin [75]. 
Interestingly, miR-101 expression inhibits the autophagy 
of hepatocellular carcinoma HepG2 cells by modulating 
Page 10 of 18Biaoxue et al. J Transl Med  (2016) 14:279 
the activity of stathmin, and enhances apoptosis of hepa-
tocellular carcinoma cells by inhibition of autophagy [76]. 
Another study shows that the expression of miR-101 is 
negatively correlated with the aggressiveness, growth 
and angiogenesis in malignant epithelial cancers. Moreo-
ver, down-regulation of miR-101 results in the accelera-
tion of cell proliferation and aggressiveness via targeting 
stathmin, indicating that stathmin is a functional target 
of miR-101 [77] (Fig. 5c). The clarification of non-coding 
RNA transcripts is likely conducive to disclose many new 
mechanisms and pathways for expounding biological 
phenomena of malignant tumors. Research shows these 
biological effects of microRNAs on tumors are involved 
in stathmin signal, influencing the cell cycle control, pro-
liferation, migration and drug resistance. Encouragingly, 
microRNA molecules are already applying into the clinic 
as diagnostic and prognostic biomarkers and therapeutic 
targets and agents.
Stathmin and chemoresistance of cancers
As shown in Table  2, higher expression of stathmin 
closely correlates with microtubule-dependent pro-
cesses and contributes to tumor cell chemoresistance. On 
the contrary, down-regulation of stathmin significantly 
reduces the chemoresistance. In this section, studies on 
relationship between stathmin and chemoresistance of 
cancers are addressed separately. Recent study demon-
strates that overexpression of stathmin influences the 
efficacy of paclitaxel, suggesting that it can be a nega-
tive prognosis indicator for non-small cell lung cancer 
patients who are treated by both platinum and paclitaxel 
chemotherapy [11]. NCI-H1299 cells (NSCLC) are evi-
dently resistant to taxol-induced cellular apoptosis and 
high expression of stathmin is perhaps a crucial determi-
nant of taxol-resistant development in NCI-H1299 cells. 
Meanwhile, ERK-mediated stathmin is involved in taxol 
resistance, because blockage of ERK signal improves the 
sensitivity of tumor cells to taxol [78, 79]. Over-expres-
sion of antiapoptotic protein Bcl-2 has been shown to 
induce chemoresistance. However, blockade of stath-
min and Bcl-2 expression can sensitize lung cancer cells 
to paclitaxel [80]. Dramatically, knockdown of stathmin 
combined with paclitaxel remarkably promotes the effi-
cacy of inhibiting proliferation of esophageal squamous 
cell cancer [81], and leads to a significantly higher pro-
portion of cells at G2/M phase, and this antiproliferative 
effect was accompanied by an increase in apoptosis rates 
and morphology changes [82].
After treated by paclitaxel or vincristine, esophageal 
squamous cell carcinoma (ESCC) cells of stathmin silenc-
ing are more likely to enter G2 but less likely to enter 
mitosis than control cells, suggesting that silencing of 
stathmin gene increases sensitivity of ESCC to paclitaxel 
and vincristine through G2/M phase block [16]. Over-
expression of stathmin reduces microtubule dynamic-
ity of cells and sensitivity to taxol, which mainly because 
overexpression of stathmin protects the cells from taxol-
induced abnormal mitoses to lead to taxol resistance 
[83]. However, combination of anti-stathmin therapy and 
taxol had a more profound inhibition of tumorigenic-
ity, as both agents target the microtubule pathway [48]. 
In addition, combined treatment of zoledronic acid and 
Fig. 5 Study progress of stathmin and MicroRNAs. a Over-expression of miR-31 restores chemo-response by reducing stathmin expression; 
miR-101/stathmin pathway contributes to radioresistance in human NPC; down-regulation of miR-193b promotes migration and proliferation of 
tumor cells by targets stathmin; miR-223 regulates stathmin by JNK signaling pathway to regulate MPM cell motility; b up-regulation of miR193b 
reduces proliferation and migration by inhibiting stathmin and uPA; silencing of miR-210 promotes proliferation of cancerous cells; transfection of 
miR-142 and miR-223 decreases expression of stathmin and IGF-1R to inhibit proliferation of cancerous cells; c microrna-9 inhibits cell proliferation, 
vasculogenic mimicry and tumor growth through controlling stathmin expression; miR-101 suppresses autophagy via targets stathmin and down-
regulation of miR-101 is linked to the increase of cellular proliferation and invasiveness. miRNAs small non-coding regulatory RNAs, JNK c-JunN-
terminalkinase, uPA urokinase-type plasminogen activator, IGF-1R insulin-like growth factor-1 receptor, MPM malignant pleural mesothelioma
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Table 2 The research progress of stathmin and chemoresistance
Publications Cancer type Cell lines Tissues Anticancer drugs Notes
Sun [11] Non-small cell lung cancer No Yes Platinum; paclitaxel High level of stathmin exhibits poor 
response to chemotherapy
Lin [78] Yes No Taxol Inhibition of stathmin expression increases 
sensitivity to taxol and promotes cellular 
apoptosis in NCI-H1299 cells
Lin [79] Yes No Taxol ERK-mediated stathmin is involved in taxol 
resistance of NCI-H1299 cells; blockage 
of ERK signal improves sensitivity of 
tumor cells to taxol
Han [80] Yes No Paclitaxel Inhibition of stathmin and Bcl-2 expres-
sion can sensitize lung cancer cells to 
paclitaxel
Feng [82] Esophageal squamous  
carcinoma
Yes No Paclitaxel Combined chemotherapeutic agent pacli-
taxel and stathmin siRNA can potentially 
enhance the therapeutic outcomes 
of paclitaxel in treating esophageal squa-
mous cell cancer (ESCC)
Wang [16] Yes No Paclitaxel Silencing of stathmin gene can increase 
sensitivity of ESCC to paclitaxel and 
vincristine through G2/M phase block
Zhu [81] Yes No Paclitaxel Stathmin silencing by siRNA enhances 
sensitivity of esophageal cancer cells 
Eca-109 to paclitaxel and induces 
apoptosis
Balasubramani [83] Breast cancer Yes No Taxol Stathmin overexpression protects the cells 
from taxol-induced abnormal mitoses, 
and thus induces taxol resistance
Miceli [48] Yes No Taxol Combination of anti-stathmin therapy and 
taxol has a more profound inhibition of 
tumorigenicity
Oda [84] Yes No Zoledronic acid; gefitinib Down-regulation of stathmin contributes 
to the effect that combined treatment of 
Zoledronic acid (Zol) and gefitinib inhib-
its both invasion and cell proliferation of 
the bone-seeking clone of breast cancer
Meng [61] Gastric cancer Yes No Docetaxel Stathmin siRNA can improve the che-
mosensitivity of gastric cancer cells to 
docetaxel and promote apoptosis
Li [24] Yes No Docetaxel Stathmin mediates docetaxel resistance in 
transcription factor forkhead box protein 
M1 (FOXM1)FOXM1-silenced gastric 
cancer cells
Liu [25] Yes No Docetaxel Inhibition of stathmin enhances the inhibi-
tory effects of docetaxel on the prolifera-
tion of gastric cancer cells
Werner [85] Endometrial carcinoma Yes Yes Paclitaxel Knock-down of stathmin improves 
sensitivity to paclitaxel in endometrial 
carcinoma cells
Wosnitzer [35] Bladder cancer No Yes Taxane Bladder cancer those who have tumors 
with low tau/stathmin protein expres-
sion show a better response to taxane
Mitra [86] Retinoblastoma Yes Yes Paclitaxel Inhibition of stathmin enhances the cyto-
toxic effect of paclitaxel
Song [63] Glioma Yes No Temozolomide Stathmin silencing inhibits invasion and 
enhances chemotherapy sensitivity of 
stem cells derived from glioma cells
Feng [87] Osteosarcoma Yes No Arsenic trioxide;  
doxorubicin
Down-regulation of stathmin significantly 
enhances reversion of ADM resistance in 
MG63/dox by As2O3
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gefitinib synergistically inhibits both invasion and cell 
proliferation of the bone-seeking clone, but not those of 
the breast cancer MDA-MB-231 cells. Down-regulation 
of stathmin of these cooperative effects suggests that it 
may be a promising target molecule for blocking bone 
metastasis of breast cancer [84].
Research shows that stathmin silencing recovers the 
chemosensitivity of gastric cancer cells to docetaxel, 
arrests cells at the sub-G1 stage, induces apoptosis and 
inhibits the growth of transplantation tumor [61]. Over-
expression of transcription factor forkhead box protein 
M1 (FOXM1) mediates resistance to docetaxel-induced 
apoptosis in gastric cancers, and stathmin correlates with 
resistance to docetaxel in FOXM1-silenced gastric can-
cer cells, indicating that stathmin is effective downstream 
signal of FOXM1 [24]. Moreover, depletion of stathmin 
by antisense oligodeoxynucleotide promotes the antitu-
mor effects of docetaxel to gastric cancer cells, and com-
bination treatment of stathmin inhibition and docetaxel 
shows a synergistic effect [25]. A protein-binding assay 
reveals that p27 can be bounded to stathmin of cytoplasm 
in extrahepatic cholangiocarcinoma (EHCC) cells; more-
over, down-regulation of stathmin leads to accumulation 
of p27, which suppresses proliferation and promotes sen-
sitivity of EHCC cells to paclitaxel [18]. Knock-down of 
stathmin enhances sensitivity to paclitaxel in endome-
trial carcinoma cells [85] and also enhances the cytotoxic 
effect of paclitaxel to retinoblastoma [86]. Inspiringly, 
in bacillus Calmette–Guérin refractory bladder cancer, 
patients who have tumors with low stathmin expression 
seem to have a better response to taxane therapy [35].
Glioma stem cells (GSCs) are usually resistant to chem-
otherapy and radiotherapy, but silencing of stathmin can 
improve the sensitivity of glioma stem cells to temozo-
lomide [63]. Arsenic trioxide (As2O3) and doxorubicin 
(ADM) combination treatment markedly inhibits cell 
proliferation of ADM-resistant MG63 (MG63/dox) oste-
osarcoma cells, and induces apoptosis of MG63/dox cells. 
Surprisingly, down-regulation of stathmin significantly 
enhances the reversion of ADM resistance in MG63/
dox by As2O3, and As2O3 also reverse ADM resistance in 
MG63/dox cells by down-regulation of stathmin [87]. In 
addition, 5-FU chemoresponse to the classical colorec-
tal cancer can be improved by silencing of stathmin via 
a caspase-6 (CASP6)-dependent signal. Interestingly, the 
function of stathmin is independent of p53 but requires 
phosphorylations at S25 or S38 [88].
From the above, we can say that assessment of stathmin 
expression should be considered to use for selection of 
patients before chemotherapy of some drugs. In addition, 
research on the relationship between chemoresistance 
and stathmin should be reinforced, which will be useful 
to identify a potential chemoresistance marker and to 
develop a new molecular targeted drug.
Stathmin‑dependent molecular targeting therapy based 
on interfering with stathmin function
In the last 5  years, many investigations have suggested 
that stathmin is a potential target for treatment of solid 
malignant tumors. Especially, a variety of target-specific 
anti-stathmin effectors, including ribozymes, monoclo-
nal antibody, shRNA and siRNA have been used exten-
sively to decrease expression of stathmin in vitro and vivo 
to investigate the therapeutic strategies targeted towards 
stathmin.
As shown in Table 3, these studies point out that down-
regulation of stathmin significantly reduces cell prolif-
eration, clonal growth, cell motility and metastasis, and 
increase apoptosis of malignant tumors. For instance, 
knockdown of stathmin significantly reduces pancreatic 
cancer cell viability, colony formation, and even retards 
pancreatic tumor growth in nude mice [27].Although 
leukemia is not a solid tumor, stathmin silencing still 
reduces cell proliferation and clonogenicity of U937 and 
Namalwa leukemia cells [66]. More widely, siRNA-medi-
ated silencing of stathmin has been shown to suppress 
the proliferation, invasion and metastasis of nasopharyn-
geal carcinoma (NPC) cells [60], hepatoma [4], ret-
inoblastoma [86], endometrial carcinoma [33], bladder 
cancer [36] and glioma [89], and significantly induces the 
apoptosis of tumor cells [54, 60, 62]. Adenovirus-medi-
ated gene transfer of anti-stathmin ribozyme inhibits cell 
Table 2 continued
Publications Cancer type Cell lines Tissues Anticancer drugs Notes
Wu [88] Colorectal cancer Yes No 5-fluorouracil Silencing of stathmin significantly 
improves chemoresponse to the classi-
cal colorectal cancer therapeutic agent, 
5-FU
Watanabe [18] Extrahepatic cholangiocarcinoma Yes Yes Paclitaxel Silencing of stathmin inhibits proliferation 
and increases sensitivity of extrahepatic 
cholangiocarcinoma cells to paclitaxel
NCI-H1299 lung adenocarcinoma cell lines, ERK extracellular regulated protein kinases, Bcl-2 B-cell lymphoma-2, ESCC esophageal squamous cell cancer, shRNA short 
hairpin RNA, siRNA small interfering RNA, FOXM1 transcription factor forkhead box protein M1, ADM doxorubicin, As2O3 arsenic trioxide, 5-FU 5-fluorouracil
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Table 3 Summary of stathmin targeted treatment against human tumors
Publication Cancer type Molecule and mechanism Activity Notes
Lu [27] Pancreatic Cancer Inhibitors of stathmin  
expression
mRNA downregulation Knockdown of stathmin sig-
nificantly reduces pancreatic 
cancer cell viability, colony 
formation. Furthermore, silence 
of stathmin retards pancreatic 
tumor growth in nude mice
Machado-Neto [29] Leukemia siRNA mRNA downregulation Stathmin silencing in U937 
and Namalwa leukemia cells 
reduces cell proliferation and 
clonogenicity
Wu [60] Nasopharyngeal carcinoma siRNA mRNA downregulation The siRNA-mediated silencing of 
stathmin suppresses prolifera-
tion, invasion and metastasis, 
and induces apoptosis of 
nasopharyngeal carcinoma 
(NPC) cells
Miceli [48] Breast cancer Ribozyme mRNA downregulation Adenovirus-mediated gene trans-
fer of anti-stathmin ribozyme 
inhibits proliferation and clono-
genicity in both ER-positive and 
ER-negative breast cancer cells
Wang [77] siRNA mRNA downregulation Knockdown of stathmin attenu-
ates down-regulation of miR-
101-mediated enhancement of 
cell growth and metastasis
Long [55] shRNA mRNA downregulation Stathmin promoter-driving 
Aurora A shRNA adenoviral sys-
tem has a potential use, which 
acts as adjuvant tumor-specific 
therapy method, in treatment of 
human breast carcinomas
Nie [3] Lung cancer siRNA mRNA downregulation Knockdown of stathmin in lung 
cancer cells results in a decrease 
in cellular proliferation and 
invasion
Yuan [54] Monoclonal antibodies Protein downregulation Monoclonal antibodies against 
stathmin inhibit proliferation of 
human lung carcinoma QG-56 
cells and result in a significantly 
higher apoptosis rate
Hsieh [4] Hepatoma siRNA mRNA downregulation Silencing of stathmin expression 
via RNA interference sup-
presses invasion activity, while 
ectopic expression of stathmin 
enhances cell invasion and 
caused polyploidy of cells
Wang [16] Esophageal squamous cell 
carcinoma
shRNA-transfected mRNA downregulation Flow cytometry and mitotic index 
assays show that knockdown of 
stathmin in esophageal squa-
mous cell carcinoma Eca109 
and TE-1 cells leads leads to cell 
cycle arrest in G2/M phase
Liu [13] siRNA mRNA downregulation Knockdown of stathmin with 
siRNA impairs cell migration 
in esophageal squamous cell 
carcinoma KYSE30 and KYSE410 
cells
Wang [14] shRNA plasmid mRNA downregulation Down-regulation of stathmin sig-
nificantly inhibits cell prolifera-
tion, cell migration in vitro, and 
tumorigenicity in vivo
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proliferation and clonogenicity in both ER-positive and 
ER-negative breast cancer cells [48] and knockdown of 
stathmin can attenuate the miR-101-mediated enhance-
ment of cell growth and metastasis [77]. Stathmin pro-
moter-driving Aurora A shRNA adenoviral system may 
has potential use, which is considered as adjuvant tumor-
specific therapy method, in the treatment of human 
breast carcinomas [55]. To lung cancer cells, knockdown 
of stathmin results in a remarkable decrease in cellu-
lar proliferation and invasion [3], and monoclonal anti-
bodies against stathmin also inhibit the proliferation of 
human lung carcinoma QG-56 cells, and even result in a 
significantly higher apoptosis rate [54]. Moreover, knock-
down of stathmin impairs cell proliferation and migra-
tion of esophageal squamous cells [13, 14, 16], and leads 
to cell cycle arrest in G2/M phase [16].
The depletion of stathmin by antisense oligodeoxynu-
cleotide significantly inhibits the proliferation of gastric 
cancer cells [25, 90]. Excitedly, the local injection of stath-
min lentivirus-delivered shRNA could be used to treat 
early localized human gastric carcinoma [91]. Bifunctional 
small hairpin RNAs (bi-shRNAs) is functional miRNA/
siRNA composite; one study shows that a single intra-
tumoral injection of pbi-sh-stathmin reduces growth of 
Table 3 continued
Publication Cancer type Molecule and mechanism Activity Notes
Machado-Neto [62] Myeloproliferative neoplasms siRNA mRNA downregulation Silencing of stathmin significantly 
reduces cell proliferation and 
clonal growth, and increases 
apoptosis induced by ruxolitinib
Mitra [86] Retinoblastoma Short interfering RNA mRNA downregulation Short interfering RNA-mediated 
transient stathmin down-
regulation results in a marked 
inhibition of retinoblastoma cell 
proliferation and cell invasion 
in vitro
He [33] Endometrial carcinoma siRNA mRNA downregulation Knockdown of stathmin inhibits 
endometrial carcinoma cell 
aggressive behaviors.
Liu [25] Gastric cancer Antisense
oligodeoxynucleotide
mRNA downregulation Stathmin transfected by antisense 
oligodeoxynucleotide signifi-
cantly inhibits proliferation of 
gastric cancer SGC 7901 cells
Akhtar [91] shRNA mRNA downregulation Stathmin shRNA-treated tumors 
are significantly regressed as 
compared with that of the 
tumor injected with non-
silencing shRNA, proposing a 
potential use of local injection 
of lentivirus-delivered shRNA for 
the treatment of early localized 
human gastric carcinoma
Akhtar [90] siRNA mRNA downregulation Lentiviral-mediated RNA interfer-
ence targeting stathmin gene 
in human gastric cancer cells 
inhibits proliferation in vitro and 
tumor growth in vivo
Hemdan [36] Bladder cancer siRNA mRNA downregulation Growth and migration of urinary 
bladder cancer cell line T24 cells 
are significantly reduced by 
stathmin-siRNA
Dong [89] Glioma siRNA mRNA downregulation When down-regulation of 
stathmin, cell viability of glioma 
is reduced, apoptosis rate 
increases and migration of 
vascular endothelial cells is sup-
pressed significantly
mRNA, messenger RNA, U937 histiocytic lymphoma cells was established by Dr. K. Nilsson’s laboratory in 1974, shRNA short hairpin RNA, siRNA small interfering RNA, 
NPC nasopharyngeal carcinoma, ER estrogen receptor, miR small non-protein-coding regulatory RNAs, Aurora A Aurora kinase A, QG-56 human lung carcinoma QG-56 
cells, Eca109 and TE-1 cells esophageal squamous cell carcinoma Eca109 and TE-1 cells, KYSE30 and KYSE410 esophageal squamous cell carcinoma KYSE30 and KYSE410 
cells, SGC 7901 gastric cancer SGC 7901 cells, T24 bladder cancer cell line T24 cells
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tumor xenograft derived from colorectal cancer CCL-247 
cells, and also significantly inhibits the growth of tumor-
grafts derived from primary melanoma and osteosarcoma 
xenograft [92]. In human cancers, stathmin is usually over-
expressed and anti-stathmin treatment usually reduces cell 
proliferation, clonal growth, cell motility, metastasis and 
increases apoptosis. So, an‘anti-stathmin’ targeted therapy 
could be a potential strategy to cure malignant tumors.
Perspective and limitation
Up to now, we still know relatively little about how the 
stathmin regulates tumor proliferation, motility, migra-
tion and occurence of metastasis. However, the abnormal 
expression of stathmin in tumor cells has provided to be 
a feasible approach for the development of stathmin-
dependent molecular targeting therapy. This way is also 
fraught with new challenges, for instance, efficient mol-
ecules and compounds able to specifically reduce stath-
min expression and decrease stathmin activity have not 
been developed, yet. The clinical application of stathmin-
dependent molecular targeting therapy is lagging way 
behind, which needs further hard study to explore  and 
discover. In addition, combination treatment of anti-stath-
min and other chemotherapy drugs still needs to further 
study. Anyway, elucidating the function of the stathmin in 
malignant tumors will effectively disclose the mechanisms 
of tumor progress and metastasis as well as greatly pro-
mote the development of new anticancer therapies.
Conclusion
Stathmin expression has been found to be increased 
in a variety of cancers and high expression of stathmin 
can potentially promote cell proliferation, motility and 
metastasis of malignant tumors. However, many target-
specific anti-stathmin investigations have been demon-
strated to reduce cell proliferation, clonal growth, cell 
motility and metastasis, and to increase apoptosis of 
malignant tumors. Whether or not stathmin proves to be 
a significant therapeutic target, the identification of spe-
cific target, development of effective therapeutic drugs 
and construction of drug delivery vehicles, will all bring 
a new challenge. Hopefully, this understanding predicts 
that stathmin-dependent molecular targeting therapy for 
malignant tumor will soon come out.
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